Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2024 Results

Rhea-AI Summary

Legend Biotech (NASDAQ: LEGN), a global leader in cell therapy, has announced it will host an investor conference call on Tuesday, March 11, 2025, at 8:00 am ET to review its fourth quarter and full year 2024 financial results.

During the webcast and conference call, senior leadership will provide an overview of Legend Biotech's quarterly and fiscal year performance. Investors and interested parties can join the live audio webcast via a provided weblink.

A replay of the webcast and the earnings news release will be made available through the Investor Relations section of Legend Biotech's website under the Events and Presentation section approximately two hours after the call concludes.

SOMERSET, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, March 11, 2025, to review fourth-quarter and full-year 2024 results.

During the webcast and conference call, senior leaders will provide an overview of Legend Biotech’s quarter and fiscal year performance.

Investors and other interested parties may join the live audio webcast of the call via this weblink.

A replay version of the webcast and earnings news release will be available through the Investor Relations section of Legend Biotech’s website under the Events and Presentation section approximately two hours after the call concludes.

ABOUT LEGEND BIOTECH

With over 2,500 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. The company is at the forefront of the CAR-T cell therapy revolution with CARVYKTI^®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the US, Legend is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, the company plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.

Learn more at www.legendbiotech.com and follow us on X (formerly Twitter) and LinkedIn.

INVESTOR CONTACT:

Caroline Paul
Tel: (973) 650-5832
caroline.paul@legendbiotech.com

PRESS CONTACT:
Mary Ann Ondish
Tel: (914) 552-4625
media@legendbiotech.com

FAQ

When will Legend Biotech (LEGN) release its Q4 and full-year 2024 financial results?

Legend Biotech will release its Q4 and full-year 2024 financial results on Tuesday, March 11, 2025, during an investor conference call scheduled for 8:00 am ET.

How can investors access Legend Biotech's (LEGN) Q4 2024 earnings call?

Investors can access Legend Biotech's Q4 2024 earnings call via a live audio webcast through the weblink provided by the company. A replay will be available on the company's website approximately two hours after the call.

What will be discussed during Legend Biotech's (LEGN) upcoming earnings call on March 11, 2025?

During the March 11, 2025 call, Legend Biotech's senior leadership will provide an overview of the company's quarterly and fiscal year performance for Q4 and full-year 2024.

Where can investors find Legend Biotech's (LEGN) Q4 2024 earnings release after the conference call?

Investors can find Legend Biotech's Q4 2024 earnings release in the Investor Relations section of the company's website under the Events and Presentation section approximately two hours after the call concludes.